35H Stock Overview
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Homology Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.83 |
| 52 Week High | US$1.26 |
| 52 Week Low | US$0.31 |
| Beta | -0.11 |
| 11 Month Change | 5.06% |
| 3 Month Change | 73.64% |
| 1 Year Change | 4.98% |
| 33 Year Change | -89.49% |
| 5 Year Change | -96.65% |
| Change since IPO | -94.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 35H | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.8% | -0.2% | 2.8% |
| 1Y | 5.0% | -22.2% | 4.2% |
Return vs Industry: 35H underperformed the German Biotechs industry which returned 35.3% over the past year.
Return vs Market: 35H underperformed the German Market which returned 6.4% over the past year.
Price Volatility
| 35H volatility | |
|---|---|
| 35H Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 35H's share price has been volatile over the past 3 months.
Volatility Over Time: 35H's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 7 | n/a | www.homologymedicines.com |
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies.
Homology Medicines, Inc. Fundamentals Summary
| 35H fundamental statistics | |
|---|---|
| Market cap | €49.80m |
| Earnings (TTM) | -€104.32m |
| Revenue (TTM) | €1.07m |
46.6x
P/S Ratio-0.5x
P/E RatioIs 35H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 35H income statement (TTM) | |
|---|---|
| Revenue | US$1.16m |
| Cost of Revenue | US$62.00m |
| Gross Profit | -US$60.85m |
| Other Expenses | US$52.12m |
| Earnings | -US$112.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.94 |
| Gross Margin | -5,263.49% |
| Net Profit Margin | -9,771.71% |
| Debt/Equity Ratio | 0% |
How did 35H perform over the long term?
See historical performance and comparison